Tags : adalimumab)

Biosimilars

Sandoz Launches Hyrimoz (biosimilar, adalimumab) in Canada

Shots: The company expands its portfolio with the marketing of the 5th biosimilars in Canada. Hyrimoz is indicated for use in nine indications of the reference (Humira) in the field of rheumatology, gastroenterology and dermatology Sandoz Canada has completed the pCPA negotiations for Hyrimoz, which is the first step in securing public reimbursement Hyrimoz is […]Read More